References
1Maruhashi T, Kihara Y, Higashi Y. Bilirubin and endothelial function. J Atheroscler Thromb 2019; 26: 688-96.
2Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 2013; 19: 6398-407.
3Das S, van Landeghem FKH. Clinicopathological spectrum of bilirubin encephalopathy/kernicterus. Diagnostics (Basel) 2019; 9: 24.
4Olusanya BO, Ogunlesi TA, Slusher TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child 2014; 99: 1117-21.
5Shapiro SM. Bilirubin toxicity in the developing nervous system. Pediatr Neurol 2003; 29: 410-21.
6Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol 2005; 25: 54-9.
7Martich-Kriss V, Kollias SS, Ball WS Jr. MR findings in kernicterus. AJNR Am J Neuroradiol 1995; 16: 819-21.
8Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985; 75: 393-400.
9Bhutani VK, Wong RJ. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol 2013; 2: 61-9.
10Assefa Neknek G, Woldemichael K, Moges A, Zewdneh Solomon D. MRI of bilirubin encephalopathy (kernicterus): a case series of 4 patients from Sub-Saharan Africa, May 2017. Radiol Case Rep 2018; 13: 676-9.
11Ho VB, Fitz CR, Chuang SH, Geyer CA. Bilateral basal ganglia lesions: pediatric differential considerations. Radiographics 1993; 13: 269-92.
